Peter Schwartz, MD
John Slade Ely Professor Emeritus of Obstetrics, Gynecology, and Reproductive SciencesCards
Appointments
Additional Titles
Vice Chair, Gynecology
Contact Info
Obstetrics, Gynecology & Reproductive Sciences
PO Box 208063
New Haven, CT 06520-8063
United States
Appointments
Additional Titles
Vice Chair, Gynecology
Contact Info
Obstetrics, Gynecology & Reproductive Sciences
PO Box 208063
New Haven, CT 06520-8063
United States
Appointments
Additional Titles
Vice Chair, Gynecology
Contact Info
Obstetrics, Gynecology & Reproductive Sciences
PO Box 208063
New Haven, CT 06520-8063
United States
About
Titles
John Slade Ely Professor Emeritus of Obstetrics, Gynecology, and Reproductive Sciences
Vice Chair, Gynecology
Biography
Dr. Peter Schwartz has been a member of the Yale Cancer Center since he joined the Yale School of Medicine Faculty in 1975. He was the first Director of the Division of Gynecologic Oncology, which he formed in 1978, and the first Director of the Gynecologic Oncology Fellowship Training Program, which was approved by the American Board of Obstetrics and Gynecology, Division of Gynecologic Oncology in 1980. Dr. Schwartz has served as President of the New Haven Obstetrical Society, The New England Association of Gynecologic Oncologists, The Felix Rutledge Society and The Society for Gynecologic Oncology. His research has focused on gynecologic cancers and their treatment. He is recognized as an international expert on the management of the rare germ cell malignancies, as well as introducing neoadjuvant chemotherapy into the treatment of the common advanced stage epithelial ovarian cancers which now has been accepted as a standard treatment by the National Comprehensive Cancer Network for the United States. He performed the first prospective randomized trial incorporating hormonal therapy with conventional platinum-based chemotherapy based on laboratory research at Yale identifying estrogen receptor proteins in epithelial ovarian cancers. He reported the first series of gynecologic cancer patients to have massive hemorrhage controlled by selective arteriography and transcatheter embolization, coil placement or balloon catheter placement and subsequently showed these techniques could also be employed to control massive postpartum hemorrhage. His clinical studies on the management of uterine serous cancer established a very successful standard therapy for early stage disease, which previously had been associated with an extremely poor prognosis. He has had a strong interest in the early detection of ovarian cancer and established the Yale Early Detection Program for Ovarian Cancer in 1990, one of the first such programs in the United States. That program was based on prior tumor marker research and diagnostic imaging studies he performed with other collaborators at Yale. Dr. Schwartz is a member of the editorial boards of seven professional journals, has served on numerous Department and Yale Cancer Center committees and currently serves as a member of the Oncology Patient Safety and Quality Council and the Smilow Leadership Council.
Appointments
Obstetrics, Gynecology & Reproductive Sciences
EmeritusPrimaryObstetrics, Gynecology & Reproductive Sciences
Senior Research ScientistSecondary
Other Departments & Organizations
Education & Training
- Fellow
- MD Anderson Cancer Center, Houston, Texas (1975)
- Resident
- Yale-New Haven Hospital (1971)
- Surgical Internship
- University of Kentucky (1966)
- MD
- Albert Einstein College of Medicine (1966)
- BS
- Union College (1964)
Board Certifications
Gynecologic Oncology
- Certification Organization
- AB of Obstetrics & Gynecology
- Original Certification Date
- 1979
Obstetrics & Gynecology
- Certification Organization
- AB of Obstetrics & Gynecology
- Original Certification Date
- 1973
Research
Overview
Ovarian cancer is currently the fifth most common cancer in American women and the fourth most common cause of female cancer deaths. A lack of early warning symptoms and a lack of tests highly sensitive for detecting the disease are the major cause for the high death rate. My research is involved with early detection of ovarian cancer by screening a population of women who have at least one first degree relative with ovarian cancer, thereby making them at higher risk than the population at large for the disease.
My research is also involved with identifying tumor markers which may be useful in early detection of ovarian cancer and in monitoring women who have themselves experienced ovarian cancer. We are interested in new and innovative ways of treating patients with ovarian cancer and are enroll women in a prospective trial of neoadjuvant chemotherapy. Finally, we see a large number of women at Yale with an aggressive form of uterine cancer, uterine papillary serous cancer. I have developed new clinical approaches that have been very successful in the treatment of women with early stages of this disease and am collaborating with colleagues in studying the molecular biology of this disease in order to develop new treatment strategies.
Neoadjuvant chemotherapy in the treatment of patients with advanced ovarian cancer
Management strategies for women with uterine papillary serous cancer
Early detection of ovarian cancer
Treatment of the elderly with ovarian and/or uterine cancer
Medical Research Interests
ORCID
0000-0002-0845-3624
Research at a Glance
Yale Co-Authors
Publications Timeline
Research Interests
Alessandro Santin, MD
Gloria Huang, MD, FACOG
Pei Hui, PhD, MD
Masoud Azodi, MD
Natalia Buza, MD
Elena Ratner, MD, MBA
Ovarian Neoplasms
Uterine Neoplasms
Uterine Cervical Neoplasms
Vulvar Neoplasms
Vaginal Neoplasms
Publications
2024
Randomized phase II trial of weekly ixabepilone with or without biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer: Updated survival and subgroup analyses
Roque D, Siegel E, Buza N, Bellone S, Huang G, Andikyan V, Clark M, Azodi M, Schwartz P, Rao G, Xu F, Hui P, Altwerger G, Ratner E, Santin A. Randomized phase II trial of weekly ixabepilone with or without biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer: Updated survival and subgroup analyses. Gynecologic Oncology 2024, 190: s299-s301. DOI: 10.1016/j.ygyno.2024.07.449.Peer-Reviewed Original ResearchPre-clinical efficacy of RAF/MEK clamp avutometinib in combination with FAK inhibition for low-grade serous ovarian cancer
McNamara B, Greenman M, Demirkiran C, Mutlu L, Hartwich T, Bellone S, Manavella D, Zipponi M, Yang-Hartwich Y, Yang K, Ratner E, Schwartz P, Santin A. Pre-clinical efficacy of RAF/MEK clamp avutometinib in combination with FAK inhibition for low-grade serous ovarian cancer. Gynecologic Oncology 2024, 190: s36. DOI: 10.1016/j.ygyno.2024.07.058.Peer-Reviewed Original ResearchEV016/#559 Preclinical activity of datopotamab deruxtecan, a novel trophoblast cell-surface antigen 2 (TROP2) directed antibody-drug conjugate targeting TROP2 in high grade serous ovarian carcinoma
Mcnamara B, Greenman M, Bellone S, Demirkiran C, Mutlu L, Hartwich T, Yang-Hartwich Y, Ratner E, Schwartz P, Santin A. EV016/#559 Preclinical activity of datopotamab deruxtecan, a novel trophoblast cell-surface antigen 2 (TROP2) directed antibody-drug conjugate targeting TROP2 in high grade serous ovarian carcinoma. 2024, a91.2-a91. DOI: 10.1136/ijgc-2024-igcs.135.Peer-Reviewed Original ResearchPreclinical activity of datopotamab deruxtecan, a novel TROP2 directed antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (TROP2) in ovarian carcinoma
McNamara B, Greenman M, Bellone S, Santin L, Demirkiran C, Mutlu L, Hartwich T, Yang-Hartwich Y, Ratner E, Schwartz P, Santin A. Preclinical activity of datopotamab deruxtecan, a novel TROP2 directed antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (TROP2) in ovarian carcinoma. Gynecologic Oncology 2024, 189: 16-23. PMID: 38981151, DOI: 10.1016/j.ygyno.2024.07.002.Peer-Reviewed Original ResearchAltmetricConceptsTargets trophoblast cell-surface antigen-2Epithelial ovarian cancerAntibody-dependent cellular cytotoxicityPreclinical activityAntibody drug conjugatesOvarian cancerCell linesTumor cellsTrophoblast cell surface antigen 2Cell line-derived xenograft modelFlow cytometryCompared to tumor cellsEpithelial ovarian cancer cell linesOvarian cancer cell linesTumor cells in vitroOvarian cancer patientsPeripheral-blood lymphocytesEOC cell linesTumor growth suppressionAnnexin V-positiveGynecologic cancer mortalityIn vivo antitumor activityCells in vitroPrimary cell linesUnmet medical needTrastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody–drug conjugate, demonstrates in vitro and in vivo antitumor activity against primary and metastatic ovarian tumors overexpressing HER2
Mutlu L, McNamara B, Bellone S, Manavella D, Demirkiran C, Greenman M, Verzosa M, Buza N, Hui P, Hartwich T, Harold J, Yang-Hartwich Y, Zipponi M, Altwerger G, Ratner E, Huang G, Clark M, Andikyan V, Azodi M, Schwartz P, Santin A. Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody–drug conjugate, demonstrates in vitro and in vivo antitumor activity against primary and metastatic ovarian tumors overexpressing HER2. Clinical & Experimental Metastasis 2024, 41: 765-775. PMID: 38909139, DOI: 10.1007/s10585-024-10297-z.Peer-Reviewed Original ResearchConceptsHigh-grade serous ovarian cancerClear cell carcinomaHER2-targeting antibody-drug conjugateAntibody-drug conjugatesT-DXdReceptor over-expressionTrastuzumab deruxtecanXenograft modelCell linesOvarian clear cell carcinomaOvarian cancer cell linesTumors overexpressing HER2Biologically aggressive tumorsFluorescence in situ hybridization assaySerous ovarian cancerEffective antibody-drug conjugatesIn vivo antitumor activityMouse xenograft modelMetastatic cell linesDS-8201aCancer cell linesAggressive tumorsHER2 expressionCell carcinomaOvarian cancerRandomized phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer (NCT03093155): Updated survival and subgroup analyses
Roque D, Siegel E, Buza N, Bellone S, Huang G, Altwerger G, Andikyan V, Clark M, Azodi M, Schwartz P, Rao G, Ratner E, Santin A. Randomized phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer (NCT03093155): Updated survival and subgroup analyses. BJC Reports 2024, 2: 43. PMID: 39516558, PMCID: PMC11523995, DOI: 10.1038/s44276-024-00067-5.Peer-Reviewed Original ResearchConceptsPre-treated ovarian cancerOverall survivalBev armsDose reductionOvarian cancerTaxane responseRandomized phase 2 trialRandomized phase II trialPaclitaxel-resistant diseaseResultsThirty-seven patientsTreated with paclitaxelPhase 2 trialBiweekly bevacizumabDays 1,8,15Taxane-sensitiveUpdate survivalProgression-freePeritoneal cancerDose modificationTaxane sensitivityPlatinum resistanceSubset analysisSubgroup analysisResponse ratePatientsPreclinical in vitro and in vivo activity of the RAF/MEK clamp avutometinib in combination with FAK inhibition in uterine carcinosarcomas
Demirkiran C, Greenman M, Bellone S, McNamara B, Hartwich T, Manavella D, Mutlu L, Zipponi M, Yang-Hartwich Y, Yang K, Ratner E, Schwartz P, Coma S, Pachter J, Santin A. Preclinical in vitro and in vivo activity of the RAF/MEK clamp avutometinib in combination with FAK inhibition in uterine carcinosarcomas. Gynecologic Oncology 2024, 187: 12-20. PMID: 38703673, DOI: 10.1016/j.ygyno.2024.04.010.Peer-Reviewed Original ResearchCitationsAltmetricConceptsFocal adhesion kinaseUC cell linesWhole-exome-sequencingFAK inhibitorCell linesFocal adhesion kinase inhibitionPhosphorylated (p)‑FAKWestern blot assayRAF/MEK inhibitionUterine carcinosarcomaRAS/MAPK pathway genesPreclinical in vitroBlot assayVS-4718Cell cycle assayGenetic landscapePathway genesMAP2KGenetic alterationsDecreased p-ERKCycle assaySuperior tumor growth inhibitionBiologically aggressive tumorsGrowth inhibitionIn vitro activityIntegrated mutational landscape analysis of poorly differentiated high-grade neuroendocrine carcinoma of the uterine cervix
Bellone S, Jeong K, Halle M, Krakstad C, McNamara B, Greenman M, Mutlu L, Demirkiran C, Hartwich T, Yang-Hartwich Y, Zipponi M, Buza N, Hui P, Raspagliesi F, Lopez S, Paolini B, Milione M, Perrone E, Scambia G, Altwerger G, Ravaggi A, Bignotti E, Huang G, Andikyan V, Clark M, Ratner E, Azodi M, Schwartz P, Quick C, Angioli R, Terranova C, Zaidi S, Nandi S, Alexandrov L, Siegel E, Choi J, Schlessinger J, Santin A. Integrated mutational landscape analysis of poorly differentiated high-grade neuroendocrine carcinoma of the uterine cervix. Proceedings Of The National Academy Of Sciences Of The United States Of America 2024, 121: e2321898121. PMID: 38625939, PMCID: PMC11046577, DOI: 10.1073/pnas.2321898121.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsWhole-exome sequencingPatient-derived-xenograftsBase excision repairCopy number lossMultiregion whole-exome sequencingCopy number gainHigh-grade neuroendocrine carcinomaCNV analysisPhylogenetic analysisEvolutionary historyNeuroendocrine cervical cancerHuman papillomavirus DNAMutator phenotypeSensitivity to afatinibGenetic landscapeRecurrent mutationsRNA sequencingGene fusionsMutational landscape analysisExcision repairGenesMutationsPan-HERConsistent with deficiencyNeuroendocrine carcinomaRandomized Phase II Trial of Imiquimod with or without 9-Valent HPV Vaccine versus Observation in Patients with High-grade Pre-neoplastic Cervical Lesions (NCT02864147)
Sheth S, Oh J, Bellone S, Siegel E, Greenman M, Mutlu L, McNamara B, Pathy S, Clark M, Azodi M, Altwerger G, Andikyan V, Huang G, Ratner E, Kim D, Iwasaki A, Levi A, Buza N, Hui P, Flaherty S, Schwartz P, Santin A. Randomized Phase II Trial of Imiquimod with or without 9-Valent HPV Vaccine versus Observation in Patients with High-grade Pre-neoplastic Cervical Lesions (NCT02864147). Clinical Cancer Research 2024, 30: of1-of10. PMID: 38592381, DOI: 10.1158/1078-0432.ccr-23-3639.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsRandomized phase II trialCD4/CD8 T cellsT cellsHPV clearanceArm BNo significant differenceClinical surveillanceRate of HPV clearanceSecondary outcomesPre-neoplastic cervical lesionsCervical intraepithelial neoplasiaT cell infiltrationT cell responsesSignificant differenceCIN3 patientsIntraepithelial neoplasiaArm ACervical lesionsImiquimod groupSurveillance armVaginal suppositoriesProspective trialsArm CHPV vaccinationImiquimodPreclinical efficacy of RAF/MEK clamp avutometinib in combination with FAK inhibition in low grade serous ovarian cancer
McNamara B, Demirkiran C, Hartwich T, Bellone S, Manavella D, Mutlu L, Greenman M, Zipponi M, Yang-Hartwich Y, Yang K, Ratner E, Schwartz P, Coma S, Pachter J, Santin A. Preclinical efficacy of RAF/MEK clamp avutometinib in combination with FAK inhibition in low grade serous ovarian cancer. Gynecologic Oncology 2024, 183: 133-140. PMID: 38493021, DOI: 10.1016/j.ygyno.2024.01.028.Peer-Reviewed Original ResearchCitationsAltmetricConceptsLow grade serous ovarian carcinomaWhole-exome-sequencingGain-of-function mutationsVS-4718Preclinical efficacyLow grade serous ovarian cancerSerous ovarian cancerControl-treated miceTumor growth inhibitionWild-type KRASLoss of heterozygosityDecreased p-ERKRAF/MEK inhibitionMedian survivalOvarian cancerRecurrence rateTherapeutic optionsOral gavageTumor growthTumor samplesIn vivo activityMAPK pathway genesRAF/MEK inhibitorsP-ERKEx vivo
Academic Achievements & Community Involvement
activity Society of Gynecologic Oncologists
Professional OrganizationsMemberDetails1999 Nominating Committee Chairman, 1997 – 1998 President, Society of Gynecologic Oncologists, 1995 – 1997 President-elect, Society of Gynecologic Oncologists, 1994 Program Committee Chairman, 1992 – 1993 Vice-President, Society of Gynecologic Oncologists, 1992 Vice President, 1991-1994 Program Committee Chairman, 1990 – 1994 Duke University Cancer Center External, Advisory Committee, 1990 –Present Reproductive Scientist Development Program, Executive Committee, 1986 Program Committee Member, Council Member, By-laws Committee Member1990 - Presentactivity Operating Room Committee
CommitteesMemberDetails1999 - Presentactivity Operating Room Management Group
CommitteesMemberDetails1995 - Presentactivity Appointments and Promotions Committee
CommitteesMemberDetails1985 - Presentactivity Board of Permanent Officers
CommitteesMemberDetails1986 - Present
News
News
- October 21, 2024
In Memoriam: Peter E. Schwartz, MD
- April 15, 2024
Genetic Analysis of Rare, Often Deadly Cervical Cancer Uncovers Potential Treatments
- August 07, 2023
New Yale Study Shows Aerobic Exercise Relieves Pain for Ovarian Cancer Survivors
- July 07, 2023Source: Medicine
Bibliometric and Visualized Analysis of Highly Cited Articles on Immunotherapy for Endometrial Cancer
Get In Touch
Contacts
Obstetrics, Gynecology & Reproductive Sciences
PO Box 208063
New Haven, CT 06520-8063
United States
Locations
Obstetrics, Gynecology & Reproductive Sciences
Academic Office
Farnam Memorial Building
310 Cedar Street, Wing Gynecologic Oncology, Fl 3rd, Ste 328
New Haven, CT 06510
General Information
203.785.4014